GREY:IMVIQ - Post by User
Comment by
Biotech010on Mar 14, 2022 3:33pm
261 Views
Post# 34512781
RE:RE:prestigious oral presentation spot at AACR
RE:RE:prestigious oral presentation spot at AACR IMV will present an abstract poster at the AACR conference featuring updated interim data with survivin vaccine candidate maveropepimut-S (MVP-S) plus KEYTRUDA with low dose cyclophosphamide (CPA) across multiple tumor types. Recently, IMV announced that the basket trial's, phase 2, open label, multi-center study, bladder cancer cohort warranted continued enrollment based on favorable assessments. For the study, enrollment is gated by pre-determined overall response rates as a blended rate between treatment-naive and experienced patients. IMV looks to showcase early data from the cohort at the presentation:
- Safety, preliminary efficacy and pharmacodynamic (PD) analysis of MVP-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer. Abstract CT035. Abstract presenter - Olivier Rixe. April 12, 2022 in the Immunotherapy Combination Strategies in Clinical Trials Session starting at 2:30 p.m. CDT.